Regeneron Pharmaceuticals (REGN)
NASDAQ • Healthcare
May 20, 2026 at 16:00 UTC
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biotechnology company that discovers and develops medicines built on antibody and genetic insights. Its labs translate biology into candidates, clinical teams test those candidates with rigorous endpoints, and manufacturing scales successful therapies for reliable supply. The operating model favors platforms that can be reapplied across conditions, which speeds learning without cutting corners. Medical affairs focuses on clear labeling and appropriate use, and post-approval work tracks outcomes so guidance can improve. Collaborations with research centers and peers widen the scientific base while keeping control of quality and data. Within healthcare, Regeneron’s role is to move promising science into practical treatment that fits the routines of real clinics.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Regeneron Pharmaceuticals's Technical Indicators Summary
Regeneron displays a bearish technical set-up, with heavy negative momentum signaled by a deeply negative MACD and an extreme CCI reading, while the stock trades well below its short- and medium-term moving averages and under the 200-day exponential average. ADX indicates a strong trend to the downside, and on-balance volume is negative, confirming distribution. Bollinger positioning shows the market nearer the lower band even as VWAP remains slightly below the price intraday. Technical takeaway: Bearish — strong negative momentum and volume favor continuation of the downtrend.
| Indicator | Value |
|---|---|
RSI (14) | 25.75 |
Stochastic %K (14, 3, 3) | 21.64 |
CCI (20) | -251.58 |
WPR (14) | -85.50 |
Momentum (10) | -74.27 |
MFI | 50.19 |
MACD Level (12, 26) | -21.46 |
Bollinger Bands | $642.30 - $779.36 |
ATR (14) | $23.94 (3.81%) |
ADX (14) | 33.31 |
OBV | -3,076,352 |
VWAP | $622.79 |
Classic Pivot Point | $624.43 |
Fibonacci Pivot Point | $624.43 |
Simple Moving Averages | $696.99 - $736.68(5 indicators) |
Exponential Moving Averages | $682.01 - $729.17(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Closing levels show REGN still elevated versus yesterday, after a 3.09% gap and a finish at 649.76. The session wrapped with neutral sector performance (-0.12%), offering little macro push or pull. REGN edges higher as Tredje AP fonden takes a new stake, signaling renewed institutional buying amid a flat sector.
Price Change
from $647.04 close
+$2.71
Trading Volume
Below avg (1.1M)
1M
vs S&P 500 Today
Strong Outperformance
+18.41%
52-Week Position
Mid-range
50.3%
Updated: May 20, 2026 at 20:06 UTC
Quote Summary
REGN Headlines
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Regeneron outlines multi‑indication C5 strategy
April 25, 2026
Institutions Shift Positions in Major Blue-Chip Stocks
April 17, 2026
Amgen Rides Renewed GLP-1 Obesity Momentum
April 9, 2026